IDH1 and astrocytoma (excluding glioblastoma): We undertook this study to investigate the molecular marker profile of WHO grade 2/3 IDH-WT astrocytomas (‘early glioblastomas’) treated at our institute over a decade and used these markers to re-classify the tumors based on the current WHO update.